Immunologic privilege in the central nervous system and the blood-brain barrier

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 1, 2013, Pages 13-21

  Muldoon, Leslie L ^a,b   Alvarez, Jorge I ^c   Begley, David J ^d   Boado, Ruben J ^e   Del Zoppo, Gregory J ^f   Doolittle, Nancy D ^a   Engelhardt, Britta ^g   Hallenbeck, John M ^h   Lonser, Russell R ^h   Ohlfest, John R ⁱ   Prat, Alexandre ^c   Scarpa, Maurizio ^j   Smeyne, Richard J ^k   Drewes, Lester R ^l   Neuwelt, Edward A ^a,m  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MONTREAL   (Canada)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY OF PADOVA   (Italy)

^k ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^l UNIVERSITY OF MINNESOTA DULUTH   (United States)

^m PORTLAND VA MEDICAL CENTER   (United States)

more..

Author keywords

blood brain barrier; multiple sclerosis; neuroimaging; neuroinflammation; neurovascular unit

Indexed keywords

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN CANCER; CD4+ T LYMPHOCYTE; CELL INTERACTION; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; DEMYELINATION; GENETIC DISORDER; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NEUROGENIC INFLAMMATION; NEUROIMAGING; NEUROIMMUNOMODULATION;

EID: 84871921577     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.153     Document Type: Review

References (113)

1. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers inmultiple sclerosis. Biochim Biophys Acta 2011; 1812: 252-264.
2. del Zoppo GJ. Inflammation and the neurovascular unit in the setting of focalcerebral ischemia. Neuroscience 2009; 158: 972-982.
3. del Zoppo GJ. The neurovascular unit, matrix proteases, and innate inflammation.Ann NY Acad Sci 2010; 1207: 46-49.
4. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluidbarriers: function and dysfunction. Semin Immunopathol 2009; 31: 497-511.
5. Neuwelt EA, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis TP et al. Strategies foradvancing brain-barriers translational research. Lancet Neurol 2008; 7: 84-96. (Pubitemid 350258701)
6. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D et al. Engagingneuroscience to advance translational research in brain barrier biology. Nat RevNeurosci 2011; 12: 169-182.
7. Keane RW, Hickey WF. Immunology of the nervous system. Oxford UniversityPress: New York, 1997.
8. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the centralnervous system. J Clin Invest 2010; 120: 1368-1379.
9. Alvarez JI, Teale JM. Evidence for differential changes of junctional complexproteins in murine neurocysticercosis dependent upon CNS vasculature. BrainRes 2007; 1169: 98-111. (Pubitemid 47374095)
10. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migrationinto the central nervous system. Nat Rev Immunol 2003; 3: 569-581. (Pubitemid 37328676)
11. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilegeby confining immune surveillance to a two-walled castle moat surroundingthe CNS castle. Fluids Barriers CNS 2011; 8: 4.
12. Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps toneuroinflammation. J Neuropathol Exp Neurol 2008; 67: 1113-1121.
13. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T et al.Dendritic cells permit immune invasion of the CNS in an animal model ofmultiple sclerosis. Nat Med 2005; 11: 328-334. (Pubitemid 40460562)
14. Wakim LM, Woodward-Davis A, Bevan MJ. Memory T cells persisting within thebrain after local infection show functional adaptations to their tissue of residence.Proc Natl Acad Sci USA 2010; 107: 17872-17879.
15. Colton CA. Heterogeneity of microglial activation in the innate immune responsein the brain. J Neuroimmune Pharmacol 2009; 4: 399-418.
16. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the ADbrain. J Neural Transm 2010; 117: 949-960.
17. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterizationof the microglial phenotype under specific pro-inflammatory and antiinflammatoryconditions: Effects of oligomeric and fibrillar amyloid-beta.J Neuroimmunol 2009; 210: 3-12.
18. Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and thepathogenesis of neurodegenerative diseases. Exp Rev Mol Med 2011; 13: e19.
19. Bartholomaus I, Kawakami N, Odoardi F, Schlager C, Miljkovic D, Ellwart JW et al.Effector T cell interactions with meningeal vascular structures in nascent autoimmuneCNS lesions. Nature 2009; 462: 94-98.
20. Kutzelnigg A, Lassmann H. Cortical lesions and brain atrophy in MS. J Neurol Sci2005; 233: 55-59. (Pubitemid 40804816)
21. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H et al.Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med2011; 365: 2188-2197.
22. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B. Leukocyteendothelialcell crosstalk at the blood-brain barrier: a prerequisite for successfulimmune cell entry to the brain. Neuropathol Appl Neurobiol 2011; 37: 24-39.
23. Sobel RA, Hinojoza JR, Maeda A, Chen M. Endothelial cell integrin lamininreceptor expression in multiple sclerosis lesions. Am J Pathol 1998; 153: 405-415. (Pubitemid 28373652)
24. Jain P, Coisne C, Enzmann G, Rottapel R, Engelhardt B. Alpha4beta1 integrinmediates the recruitment of immature dendritic cells across the blood-brainbarrier during experimental autoimmune encephalomyelitis. J Immunol 2010;184: 7196-7206.
25. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H et al. Activatedleukocyte cell adhesion molecule promotes leukocyte trafficking into the centralnervous system. Nat Immunol 2008; 9: 137-145.
26. Ifergan I, Kebir H, Terouz S, Alvarez JI, Lécuyer MA, Gendron S et al. Roleof Ninjurin-1 in the migration of myeloid cells to CNS inflammatory lesions.Ann Neurol 2011; 70: 751-763.
27. Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonniè re L et al. Centralnervous system recruitment of effector memory CD8\+ T lymphocytes duringneuroinflammation is dependent on a4 integrin. Brain Behav Immun 2011; 134:3560-3577.
28. Vercellino M, Votta B, Condello C, Piacentino C, Romagnolo A, Merola A et al.Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation:a neuropathological study. J Neuroimmunol 2008; 199: 133-141.
29. Wolburg H, Paulus W. Choroid plexus: biology and pathology. Acta Neuropathol2010; 119: 75-88.
30. de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RQ, van der Valk P et al.Transfer of central nervous system autoantigens and presentation in secondarylymphoid organs. J Immunol 2002; 169: 5415-5423. (Pubitemid 35291638)
31. Muldoon LL, Varallyay P, Kraemer DF, Kiwic G, Pinkston K, Walker-Rosenfeld SLet al. Trafficking of superparamagnetic iron oxide particles (Combidex) frombrain to lymph nodes in the rat. Neuropathol Appl Neurobiol 2004; 30: 70-79. (Pubitemid 38178004)
32. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology inAlzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant2007; 16: 285-299. (Pubitemid 47300232)
33. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson'sdisease. Br J Pharmacol 2007; 150: 963-976. (Pubitemid 46628616)
34. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg Met al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 2009;283: 99-106.
35. Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ et al. Bloodbrainbarrier P-glycoprotein function decreases in specific brain regions withaging: a possible role in progressive neurodegeneration. Neurobiol Aging 2009;30: 1818-1824.
36. Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology.Curr Alzheimer Res 2006; 3: 437-448. (Pubitemid 46066423)
37. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, HoozemansJJ. The significance of neuroinflammation in understanding Alzheimer's disease.J Neural Transm 2006; 113: 1685-1695. (Pubitemid 44657664)
38. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ. Alpha-synucleinrelease by neurons activates the inflammatory response in a microglial cell line.Neurosci Res 2010; 69: 337-342.
39. Lee JK, Tran T, Tansey MG. Neuroinflammation in Parkinson's disease. J NeuroimmunePharmacol 2009; 4: 419-429.
40. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D et al.Common genetic variation in the HLA region is associated with late-onsetsporadic Parkinson's disease. Nat Genet 2010; 42: 781-785.
41. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D et al.Genetic evidence implicates the immune system and cholesterol metabolism inthe aetiology of Alzheimer's disease. PLoS ONE 2010; 5: e13950.
42. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference insusceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role ofmicroglia. J Neurosci 2000; 20: 6309-6316. (Pubitemid 30658427)
43. Smeyne M, Jiao Y, Shepherd KR, Smeyne RJ. Glia cell number modulates sensitivityto MPTP in mice. Glia 2005; 52: 144-152. (Pubitemid 41652918)
44. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the bloodbrainbarrier. Curr Pharm Des 2008; 14: 1566-1580.
45. Bellettato CM, Scarpa M. Pathophysiology of neuropathic lysosomal storagedisorders. J Inherit Metab Dis 2010; 33: 347-362.
46. Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Therond P, Scherman D.Neuroinflammatory and oxidative stress phenomena in MPS IIIA mousemodel: the positive effect of long-term aspirin treatment. Mol Genet Metab 2011;103: 18-25.
47. Hemsley KM, Hopwood JJ. Lessons learnt from animal models: pathophysiology ofneuropathic lysosomal storage disorders. J Inherit Metab Dis 2010; 33: 363-371.
48. Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH. Spatialand temporal correlation between neuron loss and neuroinflammation in amouse model of neuronopathic Gaucher disease. Hum Mol Genet 2011; 20:1375-1386.
49. Killedar S, Dirosario J, Divers E, Popovich PG, McCarty DM, Fu H. MucopolysaccharidosisIIIB, a lysosomal storage disease, triggers a pathogenic CNSautoimmune response. J Neuroinflammation 2010; 7: 39.
50. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogeniccascades in lysosomal storage diseases. J Biol Chem 2010; 285: 20423-20427.
51. Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH. Contribution of braininflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.Brain 2012; 135: 1724-1735.
52. Dobrenis C. Cell-mediated delivery systems. In: Platt FM, Walkley SU (eds)Lysosomal disorders of the brain. Oxford University Press: Oxford, UK, 2004,pp 339-380.
53. Stroobants S, Gerlach D, Matthes F, Hartmann D, Fogh J, Gieselmann V et al.Intracerebroventricular enzyme infusion corrects central nervous systempathology and dysfunction in a mouse model of metachromatic leukodystrophy.Hum Mol Genet 2011; 20: 2760-2769.
54. Milner R, Hung S, Wang X, Spatz M, del Zoppo GJ. The rapid decrease inastrocyte-associated dystroglycan expression by focal cerebral ischemia is protease-dependent. J Cereb Blood Flow Metab 2008; 28: 812-823. (Pubitemid 351432795)
55. Osada T, Gu YH, Kanazawa M, Tsubota Y, Hawkins BT, Spatz M et al. Interendothelialclaudin-5 expression depends on cerebral endothelial cell-matrixadhesion by beta(1)-integrins. J Cereb Blood Flow Metab 2011; 31: 1972-1985.
56. Fischer S, Wobben M, Marti HH, Renz D, Schaper W. Hypoxia-induced hyperpermeabilityin brain microvessel endothelial cells involves VEGF-mediatedchanges in the expression of zonula occludens-1. Microvasc Res 2002; 63: 70-80. (Pubitemid 34971510)
57. Okada Y, Copeland BR, Fitridge R, Koziol JA, del Zoppo GJ. Fibrin contributes tomicrovascular obstructions and parenchymal changes during early focal cerebralischemia and reperfusion. Stroke 1994; 25: 1847-1853, discussion 1853-1854.
58. Willis CL, Meske DS, Davis TP. Protein kinase C activation modulates reversibleincrease in cortical blood-brain barrier permeability and tight junction proteinexpression during hypoxia and posthypoxic reoxygenation. J Cereb Blood FlowMetab 2010; 30: 1847-1859.
59. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP et al. Activationsystems for latent matrix metalloproteinase-2 are upregulated immediately afterfocal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 1408-1419. (Pubitemid 38018259)
60. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston Jr LL, del Zoppo GJ. Focalcerebral ischemia induces active proteases that degrade microvascular matrix.Stroke 2004; 35: 998-1004. (Pubitemid 38419817)
61. Hosomi N, Lucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Rapid differentialendogenous plasminogen activator expression after acute middlecerebral artery occlusion. Stroke 2001; 32: 1341-1348. (Pubitemid 32530420)
62. Li L, Welser JV, Dore-Duffy P, Del Zoppo GJ, LaManna JC, Milner R. In the hypoxiccentral nervous system, endothelial cell proliferation is followed by astrocyteactivation, proliferation, and increased expression of the a6b4 integrin anddystroglycan. Glia 2010; 58: 1157-1167.
63. Kwon I, Kim EH, del Zoppo GJ, Heo JH. Ultrastructural and temporal changes ofthe microvascular basement membrane and astrocyte interface following focalcerebral ischemia. J Neurosci Res 2009; 87: 668-676.
64. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclearleukocytes occlude capillaries following middle cerebral arteryocclusion and reperfusion in baboons. Stroke 1991; 22: 1276-1283.
65. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ. P-selectinand intercellular adhesion molecule-1 expression after focal brain ischemia andreperfusion. Stroke 1994; 25: 202-211.
66. Sorokin L. The impact of the extracellular matrix on inflammation. Nat RevImmunol 2010; 10: 712-723.
67. Ennis SR, Keep RF. The effects of cerebral ischemia on the rat choroid plexus.J Cereb Blood Flow Metab 2006; 26: 675-683.
68. Matsumoto N, Taguchi A, Kitayama H, Watanabe Y, Ohta M, Yoshihara T et al.Transplantation of cultured choroid plexus epithelial cells via cerebrospinal fluidshows prominent neuroprotective effects against acute ischemic brain injury inthe rat. Neurosci Lett 2010; 469: 283-288.
69. Borlongan CV, Skinner SJ, Geaney M, Vasconcellos AV, Elliott RB, Emerich DF. CNSgrafts of rat choroid plexus protect against cerebral ischemia in adult rats.Neuroreport 2004; 15: 1543-1547. (Pubitemid 38971168)
70. Li W, Graeber MB. The molecular profile of microglia under the influence ofglioma. Neuro Oncol 2012; 14: 958-978.
71. Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J et al. Extracellular matrix proteinCCN1 limits oncolytic efficacy in glioma. Cancer Res 2012; 72: 1353-1362.
72. Martin TA, Mason MD, Jiang WG. Tight junctions in cancer metastasis. FrontBiosci 2011; 16: 898-936.
73. Lee J, Lund-Smith C, Borboa A, Gonzalez AM, Baird A, Eliceiri BP. Glioma-inducedremodeling of the neurovascular unit. Brain Res 2009; 1288: 125-134.
74. Cancer Genome Atlas Research N. Comprehensive genomic characterizationdefines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068.
75. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patientswith primary malignant brain tumors. J Neuroimmunol 1999; 100: 216-232. (Pubitemid 30038255)
76. Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest Jr. Effective CpG immunotherapyof breast carcinoma prevents but fails to eradicate established brainmetastasis. Clin Cancer Res 2008; 14: 5484-5493.
77. Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A et al.Site-specific anti-tumor immunity: differences in DC function, TGF-betaproduction and numbers of intratumoral Foxp3\+ Treg. Eur J Immunol 2009; 39:1323-1333.
78. Collignon FP, Holland EC, Feng S. Organ donors with malignant gliomas: anupdate. Am J Transplant 2004; 4: 15-21. (Pubitemid 38155485)
79. DeLuca I, Blachere NE, Santomasso B, Darnell RB. Tolerance to the neuronspecificparaneoplastic HuD antigen. PLoS ONE 2009; 4: e5739.
80. Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N et al. Patients withlung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8\+T cells. J Clin Invest 2009; 119: 2042-2051.
81. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys totumour immunity. Nat Rev Cancer 2004; 4: 36-44. (Pubitemid 38082152)
82. Johnson RS, Walker AI, Ward SJ. Cancer vaccines: will we ever learn? Expert RevAnticancer Ther 2009; 9: 67-74.
83. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, GoffinJ et al. Postoperative adjuvant dendritic cell-based immunotherapy in patientswith relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14: 3098-3104.
84. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al. Geneexpression profile correlates with T cell infiltration and survival in glioblastomapatients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17:1603-1615.
85. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumorlysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patientswith malignant glioma. Cancer Res 2004; 64: 4973-4979. (Pubitemid 38924545)
86. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al. Subacutemeningoencephalitis in a subset of patients with AD after Abeta42 immunization.Neurology 2003; 61: 46-54. (Pubitemid 36818745)
87. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathwayregulates innate immune system ligands of the NKG2D receptor. Nature 2005;436: 1186-1190. (Pubitemid 41232299)
88. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks suppressorsand antigen presenters: how lymphodepletion enhances T cell-mediated tumorimmunotherapy. Trends Immunol 2005; 26: 111-117.
89. Lorenzi AR, Clarke AM, Wooldridge T, Waldmann H, Hale G, Symmons D et al.Morbidity and mortality in rheumatoid arthritis patients with prolonged therapyinducedlymphopenia: twelve-year outcomes. Arthritis Rheum 2008; 58: 370-375. (Pubitemid 351294871)
90. Cui Y, Zhang H, Meadors J, Poon R, Guimond M, Mackall CL. Harnessing thephysiology of lymphopenia to support adoptive immunotherapy in lymphorepletehosts. Blood 2009; 114: 3831-3840.
91. Cucullo L, Marchi N, Hossain M, Janigro D. A dynamic in vitro BBB model for thestudy of immune cell trafficking into the central nervous system. J Cereb BloodFlow Metab 2011; 31: 767-777.
92. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S et al. RegulatoryT cells are key cerebroprotective immunomodulators in acute experimentalstroke. Nat Med 2009; 15: 192-199.
93. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drugdevelopment. Mol Interv 2003; 3: 90-10551.
94. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases.Neurotherapeutics 2008; 5: 123-127. (Pubitemid 350299297)
95. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS et al.Novel nanoliposomal CPT-11 infused by convection-enhanced delivery inintracranial tumors: pharmacology and efficacy. Cancer Res 2006; 66: 2801-2806.
96. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics.Pharm Res 2007; 24: 1772-1787. (Pubitemid 47206622)
97. Boado RJ. A new generation of neurobiological drugs engineered toovercome the challenges of brain drug delivery. Drug News Perspect 2008; 21:489-503.
98. Zhou QH, Fu A, Boado RJ, Hui EK, Lu JZ, Pardridge WM. Receptor-mediated abetaamyloid antibody targeting to Alzheimer's disease mouse brain. Mol Pharm2011; 8: 280-285.
99. Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Intravenous treatment ofexperimental Parkinson's disease in the mouse with an IgG-GDNF fusion proteinthat penetrates the blood-brain barrier. Brain Res 2010; 1352: 208-213.
100. Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Brain penetratingIgG-erythropoietin fusion protein is neuroprotective following intravenoustreatment in Parkinson's disease in the mouse. Brain Res 2011; 1382:315-320.
101. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. IntravascularAAV9 preferentially targets neonatal neurons and adult astrocytes. NatBiotechnol 2009; 27: 59-65.
102. Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurologicaldisease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brainbarrier gene delivery. Mol Ther 2011; 19: 1025-1033.
103. Xue YQ, Ma BF, Zhao LR, Tatom JB, Li B, Jiang LX et al. AAV9-mediatederythropoietin gene delivery into the brain protects nigral dopaminergicneurons in a rat model of Parkinson's disease. Gene Ther 2010; 17: 83-94.
104. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW et al. AAVvector integration sites in mouse hepatocellular carcinoma. Science 2007;317: 477. (Pubitemid 47196106)
105. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease.Neuron 2010; 66: 646-661.
106. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W et al. Glioma cancer stem cellsinduce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12:1113-1125.
107. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN et al. Intratumoralmediated immunosuppression is prognostic in genetically engineered murinemodels of glioma and correlates to immunotherapeutic responses. Clin CancerRes 2010; 16: 5722-5733.
108. Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W,Masson F et al. Immune infiltration of spontaneous mouse astrocytomas isdominated by immunosuppressive cells from early stages of tumor development.Cancer Res 2010; 70: 4829-4839.
109. Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C et al. Antitumorimmune response correlates with neurological symptoms in a dog withspontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010;28: 3371-3378.
110. Pirko I, Johnson A, Ciric B, Gamez J, Macura SI, Pease LR et al. In vivo magneticresonance imaging of immune cells in the central nervous system with superparamagneticantibodies. FASEB J 2004; 18: 179-182.
111. Weinstein J, Varallyay C, Dosa E, Gharmanov S, Hamilton B, Rooney W et al.Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonanceimaging and therapeutics in CNS pathology, a review. J Cereb Blood Flow Metab2010; 30: 15-35.
112. Villoslada P, Steinman L, Baranzini SE. Systems biology and its application to theunderstanding of neurological diseases. Ann Neurol 2009; 65: 124-139.
113. Dosa E, Guillaume DJ, Haluska M, Lacy CA, Hamilton BE, Njus JM et al. Magneticresonance imaging of intracranial tumors: intra-patient comparison of gadoteridoland ferumoxytol. Neuro Oncol 2011; 13: 251-260.